GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Regional Analysis

• North America is expected to be the largest market for workout supplement during the forecast period, accounting for over 35.7% of the market share in 2023. North America has established itself as the dominant region in the global G-protein coupled receptors market. The region is home to top research universities and numerous biotech and pharmaceutical companies that are engaged in GPCR-related research and drug development. Biopharmaceutical companies in the U.S. and Canada are continuously investing in research and development (R&D) to develop novel GPCR-targeting therapeutics. Along with an early mover advantage, these companies have access to venture capital funding and a supportive regulatory environment that encourages clinical research. The region also has a highly skilled workforce with expertise in GPCR structure determination and screening technologies. Several contract research organizations (CRO) specializing in GPCR drug discovery services are based in North America to cater to the evolving needs of pharmaceutical companies. Ongoing academic-industrial collaborations have strengthened the region's product pipelines. Consolidation activities among biotech players have further boosted North America's leadership. The easy access to research talent, infrastructure, and regional clustering of industry players makes North America an attractive destination for companies engaged in GPCR drug development.
• Asia Pacific market is expected to be the second-largest market for workout supplement market, accounting for over 25.2% of the market share in 2023. Among growing regions, Asia Pacific displays high potential due to increased investments by global pharmaceutical majors. Governments in several Asia Pacific (APAC) countries recognize biopharmaceutical as a strategic industry and provide tax incentives as well as regulatory input to foreign companies setting up local operations. For instance, China and India have emerged as leading contract research hubs, thereby providing cost-effective drug discovery services to multinational biotechs. Their large patient pools and clinical trial capabilities are helping to accelerate global clinical programs. The improved protection, market access, and talent availability have prompted global pharmaceutical giants to outsource more work to APAC. This is fueling infrastructure improvements and the region's expertise in GPCR-related areas. The expanding biopharmaceutical manufacturing base and clinical trial pipelines point towards APAC's rise as a key player.

Figure 1. Global G-Protein Coupled Receptors Market Share (%), By Region, 2023